Drug name: Gemcitabine + siRNAs


Related CSCTT Targets

ALDH1 [ref.1]P00352

Gemcitabine

Cas.no PubChem ID
95058-81-4 60750
Known Target
DNA
Ribonucleoside-diphosphate reductase large subunitP23921
Thymidylate synthaseP04818
UMP-CMP kinaseP30085
Structure
...
Introduction
Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the “faulty” nucleoside, resulting in apoptosis (cellular “suicide”). Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.

ALDH1-siRNA

Cas.no PubChem ID
Known Target
Retinal dehydrogenase 1P00352
Structure
...
Introduction
ALDH1A1 knockdown enhances cytotoxicity and apoptotic cell death induced by GEM.

Reference

  • [1] Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Duong, H. Q., et al. (2012).Int J Oncol. 41(3):855-61.
    22710732. [ 22710732 ]

Back to top